Hepatic fatty acid (FA) composition may influence steatosis development in patients with chronic hepatitis C (CHC). In a cross-sectional study, we compared the hepatic FA profile in hepatitis C patients with (n ¼ 9) and without (n ¼ 33) steatosis ($5% of hepatocytes involved). FA composition of hepatic and RBC total lipids was measured by gas chromatography. Lipid peroxidation and antioxidants in liver and plasma, blood biochemistry, and nutritional status were also assessed. Patients with steatosis had more fibrosis, higher necroinflammatory activity of their hepatitis C infection, were more often infected with genotype 3, and had lower serum cholesterol. Monounsaturated FA in the liver were higher and trans FA were lower in patients with steatosis. Lower stearic acid and higher oleic acid in hepatic total lipids suggested higher D9-desaturase activity. a-Linolenic acid in the liver was higher and the ratios of long-chain PUFA:essential FA precursors were lower for (n-3) and (n-6) PUFA. Plasma vitamin C was lower in steatosis, but RBC FA composition and other parameters did not differ. We conclude that hepatic FA composition is altered in patients with hepatitis C and steatosis, probably due to modulation of enzymatic elongation and desaturation. Oxidative stress or nutritional status does not seem to play a predominant role for development of steatosis in CHC.
Introduction
Hepatic steatosis, which is found in up to 50% of patients with chronic hepatitis C infection (CHC) 8 (1, 2) , accelerates the progression of fibrosis (1) and lowers the response rate to antiviral therapy (2, 3) . Steatosis in CHC results in part from direct steatogenic effects of the virus, especially in genotype 3 infections (2) . The hepatitis C virus directly interferes with elements of the lipid metabolism (4, 5) and can cause insulin resistance (6) , which is highly prevalent in CHC (3) . Hepatic steatosis in CHC also has a metabolic component, because high BMI, central obesity, insulin resistance, and dyslipidemia also increase the risk for fat accumulation in the liver, similar to nonalcoholic fatty liver disease (NAFLD) (1, 2) .
Alterations in hepatic lipid composition, especially a reduction in PUFA, are a factor that may also contribute to the development of steatosis, as recently proposed for NAFLD (7) (8) (9) (10) . PUFA influence gene expression in liver and skeletal muscle (11) , thereby reducing fatty acid (FA) synthesis and triacylglycerol storage and enhancing FA oxidation. Changes in tissue (n-6) and (n-3) PUFA content also affect eicosanoid synthesis, which may further promote steatosis and inflammation (11) . However, no data are available on hepatic FA composition in patients with CHC-associated steatosis. The aim of the current study was to compare the hepatic FA composition in patients with CHC and steatosis (CHC1S) to those with CHC without steatosiss. Associations with oxidative stress, nutritional status, and metabolic disturbances were also assessed.
Materials and Methods
Patients. This was a cross-sectional study. From July 2005 to November 2007, male and female ambulatory patients (age .18 y) with CHC undergoing routine liver biopsy before starting antiviral therapy were enrolled. Exclusion criteria were: alcohol consumption .20 g/d; liver disease of other etiology; anticipated need for liver transplantation within 1 y or complications of liver disease; any reasons contraindicating a liver biopsy; taking medications known to precipitate steatohepatitis, supplementation of antioxidant vitamins or PUFA, ursodeoxycholic acid, or any other experimental drug in the 6 mo prior to entry; and pregnancy or lactation. Liver tissue samples were taken at the time of the biopsy. Fasting blood work, anthropometric measurements, and food and activity protocols were obtained at the follow-up visit, usually within 3 mo after the biopsy. The study was performed according to the guidelines of the 1975 Declaration of Helsinki and was approved by the Research Ethics Board, University Health Network, Toronto, Ontario, Canada, and registered in the U.S. NIH Clinical Trials registry (NCT00444002) (12). All subjects gave their informed written consent.
Sample collection and preparation. One part of the liver sample was stored in 10% formalin buffer for histologic evaluation and another part was snap-frozen in liquid nitrogen and stored at 280°C for future analysis. Samples were thawed, weighed, and homogenized in ice-cold 20 mmol/L PBS, pH 7.3, with 5 mmol/L butylated hydroxytoluene. The suspension was aliquoted and stored at 280°C until analysis.
Blood for the measurement of oxidative stress and RBC FA was collected in EDTA-containing tubes and centrifuged (910 3 g; 10 min). Plasma and RBC were aliquoted and frozen at 280°C. Plasma for vitamin C analysis was stabilized with 10% meta-phosphoric acid (1:1) (v:v) before freezing. Samples for blood biochemistry were collected and analyzed at the Toronto Medical Laboratory at the University Health Network.
Histology. A single pathologist reviewed biopsy specimens with 2 hematoxylin-eosin-stained sections for necroinflammatory grading and 2 Masson trichrome-stained sections for assessment of fibrosis.
Large droplet steatosis was evaluated as a direct estimate of the percentage of hepatocytes containing large-droplet fat and scored using the Brunt grading system (13) . Necroinflammatory activity was assessed using the METAVIR activity index (14) . For assessment of fibrosis, we took into account that there are 2 potentially fibrosis-inducing disease processes, CHC and steatohepatitis, in which fibrosis patterns differ and could potentially coexist. To evaluate fibrosis overall, we used the METAVIR system (14) . To distinguish between cases with simple steatosis and steatohepatitis, a separate category for zone 3 fibrosis characteristic of steatohepatitis as well as hepatocellular ballooning were evaluated as per the nonalcoholic steatohepatitis activity scoring system (15) .
FA composition and oxidative stress. Liver and RBC lipids were extracted, saponified, and transmethylated. FAME were separated using an Agilent 6890 gas chromatograph equipped with a flame ionization detector and a SP2560 fused silica capillary column (Supelco; 100 m, 0.25-mm film thickness, 0.25-mm i.d.) (7, 16) . Thirty-four peaks were identified from C 14:0 to C 22:6(n-3). Results are reported as mole percent (mol%) of total lipids. The intra-assay variance was between ,1 and 3% and the interassay variance typically between ,1 and 6%.
Liver lipid peroxides (Bioxytech LPO-586), and plasma and liver antioxidant potential (Bioxytech antioxidant potential-490) were measured using commercial kits (OXIS International). Plasma vitamin C was determined with a colorimetric assay (17) , plasma a-and g-tocopherol, and retinol by HPLC (18) using 100% methanol as mobile phase on a Varian ProStar Analytical system with a ResinElut column, 5u C18, 150 3 4.60 mm (Varian Analytical Instruments).
Nutritional assessment. Anthropometric methods were described previously (7) . Briefly, BMI was calculated [weight/height 2 (kg/m
2 )] and waist circumference was measured. Body fat mass (percent of body weight) was assessed by bioelectrical impedance analysis (BIA-103, RJLsystem).
Each participant completed 1 3-d food record, including 2 weekdays and 1 weekend day, using the 2D Food Portion Visual chart (Nutrition Consulting Enterprises) to estimate portion sizes. If patients did not return their food record at follow-up, a 24-h recall was conducted.
Protocols were analyzed using Diet Analysis Plus version 7.0.1 (Thomson Wadsworth). Patients recorded their physical activity (daily life activities and sports exercises) for 7 d, including time, type and duration, and intensity of these activities. Units of exercise per day were calculated. One unit was defined as 30 min mild, 20 min moderate, 10 min strenuous, or 5 min very strenuous activity (19) .
Blood biochemistry. Fasting plasma glucose was measured by the enzymatic hexokinase method on an Architect c8000 System (Abbot Laboratories). Serum insulin was determined by RIA (Immulite 2500, Siemens Diagnostics) and serum C-peptide by an electrochemiluminescence immunoassay (Modular Analytics, Roche Diagnostics). Hemoglobin A1c in plasma was measured by ion exchange HPLC (Variant II analyzer, Bio-Rad Laboratories). We used the homeostasis model of assessment [glucose (mmol/L) 3 insulin (mU/L) / 22.5] as an indirect measure of insulin resistance (20) . Alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase in plasma as well as serum triglycerides, total cholesterol, and HDL were measured using the Architect c8000 system (Abbot Laboratories). LDL was calculated as total 2 HDL cholesterol.
Statistical analysis. To compare the CHC1S patients to those without steatosis, Mann-Whitney U test and x 2 test were used as appropriate. Spearman correlations were calculated. Values reported are median (range) or percent of valid cases. P , 0.05 was considered significant.
Results
One-hundred and five patients consented; 36 were excluded after enrolment because they met exclusion criteria, and 16 dropped out of the study. For 11 patients, not enough liver tissue was available; thus, 42 patients were analyzed. Blood work was available for 36 of these patients, anthropometric data was available for 41, and 36 provided a food record and activity log.
The median age for all patients was 46.0 (25.0-64.0) y, 50% were female, and the BMI (n ¼ 40) was 24.0 (17.2-36.3) kg/m 2 . A total of 78.6% of the patients were naïve to antiviral treatment. Thirty-three patients had no steatosis (CHC) and 9 had large-droplet steatosis in $5% of hepatocytes (10-40%) (CHC1S). The 2 groups did not differ in demographics (Supplemental Table 1 ), except for a higher cigarette consumption by the smokers in the CHC1S group [20 (20-20) vs. 4.5 (0.7-40) cigarettes/d]. Hepatitis C virus RNA, durations of infection, hepatitis C risk factors, medical history, and medication profile did not differ (Supplemental Table 1 ). The numbers of patients infected with genotype 1/2/3/4 were 22/7/3/1 in CHC and 4/0/4/0 in CHC1S. One patient with CHC1S had undetermined genotype. The prevalence of genotype 3 was higher in CHC1S (50%) than in the CHC group without steatosis (9.1%). The groups did not differ in anthropometric data (Supplemental Table 2 ) or blood biochemistry (Supplemental FA composition. The percent contribution of monounsaturated FA (MUFA) in hepatic total lipids was higher in CHC1S ( Table 2) , mainly due to higher oleic acid [18:1(n-9)] (143%). Palmitoleic acid [16:1(n-7)] was also higher (168%). Total SFA did not differ, but stearic acid (18:0) was lower in the CHC1S group (216%), resulting in a higher oleic:stearic acid ratio, a marker for stearoyl-CoA desaturase (SCD ¼ D9-desaturase) activity (Fig. 1) . Total PUFA and the (n-6):(n-3) ratio were not (Fig. 1) . The ratios of 20:4(n-6):20:3(n-6) and 18:3(n-6):18:2(n-6), which are markers for D5-desaturase and D6-desaturase, respectively, did not differ (data not shown). (Table 2 ).
FA composition in
Other measurements. Liver lipid peroxidation and liver and plasma antioxidant potential did not differ between the CHC1S and CHC groups (Supplemental Table 4 (18, 21) .
Dietary intake did not differ between the 2 patient groups (Supplemental Table 5 ), but neither group reached the recommended dietary intake for essential FA, vitamin E, or fiber, and mean vitamin C intake was below the estimated average requirement in CHC1S (22) (Supplemental Table 5 
Discussion
This study demonstrates alterations in the hepatic FA profile of patients with CHC1S compared with CHC. This was not associated with increased oxidative stress or different nutritional status. The observed changes in FA composition suggest dysregulations of enzymatic conversion steps in CHC-associated steatosis. The higher relative amount of MUFA and higher oleic:stearic acid ratio in CHC1S suggest increased activity of SCD, which is the rate-limiting enzyme in the synthesis of MUFA from SFA. SDC is considered one key enzyme for the development of hepatic steatosis, because SCD1-deficient mice are resistant to diet-induced obesity and steatosis (24) . The underlying mechanisms might involve regulation of transcription factors, like the sterol regulatory element binding protein 1, leading to decreased lipogenesis and enhanced b-oxidation (24) . Lower ratios of AA:linoleic acid and (EPA1DHA):ALA and the higher ALA in CHC1S are also consistent with dysregulation of enzymatic conversion steps, in this case, a downregulation or inhibition of desaturases or elongases (25) even if the specific indices for D5-and D6-desaturase activity did not differ. This could be due to high intersubject variation but might also suggest that the production/activity of other enzymes involved in the essential FA metabolism may be impaired.
In vitro and animal studies have shown that the hepatitis C virus is able to interfere with the FA metabolism by altering the expression of metabolically important genes (4, 5) , including SCD (26) . Therefore, it is conceivable that direct viral effects might contribute to the changes in hepatic FA profile. Variations in genes like FADS1 (D5-desaturase) and FADS2 (D6-desaturase) or SCD might also influence enzyme activity and FA composition (27, 28) . However, to our knowledge, there are currently no studies available investigating the regulation of FA metabolism in patients with CHC.
Oxidative stress is thought to be involved in the development of CHC-associated steatosis (3) . In contrast to this, oxidative stress was not higher in liver or plasma of patients with CHC1S compared with CHC patients, which might be due to the low degree of steatosis in our CHC1S group. However, liver lipid peroxides were negatively correlated with hepatic long-chain PUFA, suggesting that lipid peroxidation might contribute to the relative depletion of these FA in hepatic total lipids.
Dietary intake does not seem to play a role in altered hepatic FA composition in the CHC1S group, because the self-reported intake and plasma levels of antioxidant vitamins as well as the RBC FA profile, which reflect the dietary FA composition from the preceding 1-2 mo (29), did not differ from the CHC group. Especially trans-FA, which can inhibit elongation and desaturation of (n-6) and (n-3) PUFA (8), did not differ in diet and RBC, and hepatic trans-FA were even lower in the CHC1S patients. Thus, trans-FA do not seem to play a role for the impaired essential FA metabolism.
Metabolic parameters (anthropometry and blood biochemistry) did not differ between the 2 groups, suggesting that direct viral actions were more important than metabolic abnormalities for the development of steatosis in CHC. However, this might be influenced by the higher proportion of genotype 3 infections in the CHC1S group, because genotype 3 has direct steatogenic effects (2, 4, 5) . A separate analysis for patients with genotype 3 would be necessary but was not possible in this study due to the small sample size.
Overall, the small sample size was a study limitation, but the study was difficult to complete due to patients' reluctance to undergo liver biopsy and to provide blood and complete food diaries. In addition, small tissue samples from liver biopsies prevented FA analysis in some patients. Furthermore, the prevalence of steatosis was lower than expected, probably due to a different patient population than previously reported (1). Our patients had a lower prevalence of genotype 3, fibrosis, and inflammation and those with alcohol abuse were excluded (1). These challenges prevented us from collecting a sufficient number of patients for multivariate analysis to examine the influence of factors like genotype, gender, age, and BMI on hepatic FA composition. The small number of patients combined with the low grade of steatosis in the CHC1S group may also have prevented the detection of differences in hepatic PUFA and oxidative stress between CHC and CHC1S, as described for NAFLD compared with controls (7) (8) (9) (10) . Furthermore, the crosssectional design does not enable us to define cause-effect relations. A longitudinal study would be necessary to find out whether the observed changes in hepatic FA composition actually contribute to steatogenesis or whether they occur due to fat accumulation. Finally, the product:precursor ratios are only surrogate markers for the activity of enzymes involved in hepatic FA metabolism. Measurement of mRNA levels and enzyme activities should be included in future studies to identify the mechanisms underlying the dysregulations in FA metabolism. We found altered hepatic FA composition in patients with CHC1S compared with CHC without steatosis. Changes in the ratios of products:essential FA precursors suggest defects in the elongation and desaturation processes involved in the essential FA metabolism. Similarly, the increase of MUFA and the oleic:stearic acid ratio suggest an upregulation of D9-desaturase, which might contribute to the development of steatosis. To be able to target these dysregulations through therapeutic interventions to prevent steatosis in CHC, the underlying mechanisms have to be further investigated.
